Results 241 to 250 of about 96,147 (311)

SGLT2 inhibitor or metformin as standard treatment in early‐stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register‐based randomised trial on prevention of diabetic complications

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1327-1338, February 2026.
Abstract Aims Metformin has hitherto not been proven superior to other type 2 diabetes (T2D) medications for the prevention of organ complications. The aim of this study is to report baseline data and blinded interim analyses in the register‐based randomised clinical trial (RRCT) SMARTEST, which compares metformin and the SGLT2 inhibitor dapagliflozin ...
Jan W. Eriksson, Giovanni Fanni, Martin H. Lundqvist, Stefan Jansson, Karin Rådholm, Sheyda Sofizadeh, Vagia Patsoukaki, Albert Nilsson, Daniel Lindholm, Olov Rolandsson, Anna Norhammar, Elisabet Granstam, Björn Eliasson, Louise Bennet, Johan Sundström   +14 more
wiley   +1 more source

Portal hypertension of diverse origins: special features of hepatic haemodynamics based on perfusion computed tomography assessment. [PDF]

Pol J Radiol
Djurayeva N, Ikramov A, Babadzhanov A, Amirkhamzaev A, Abdulkhalimova K, Shamirzaev K, Sultanov A, Magzumova S.   +7 more
europepmc   +1 more source

Real‐World Effectiveness and Safety of Damoctocog Alfa Pegol in Severe and Nonsevere Patients With Hemophilia A From the Prospective, Multinational, Ongoing HEM‐POWR Study

European Journal of Haematology, Volume 116, Issue 2, Page 148-159, February 2026.
ABSTRACT Objectives To assess the effectiveness and safety of damoctocog alfa pegol in patients with severe and nonsevere hemophilia A in the fifth interim analysis of the ongoing HEM‐POWR study. Methods HEM‐POWR (NCT03932201) is a multinational, Phase 4, prospective observational study.
Mark T. Reding, María Teresa Alvarez Román, Giancarlo Castaman, Maissaa Janbain, Tadashi Matsushita, Karina Meijer, Kathrin Schmidt, Johannes Oldenburg   +7 more
wiley   +1 more source

A Case of a Young Pregnant Patient With Congenital Portal Vein Stenosis, Portal Hypertension, and Liver Cirrhosis. [PDF]

Cureus
Alzain FA, Alolaian RJ, Alolayan AJ, Alolaian AJ, Albadrani YH.   +4 more
europepmc   +1 more source

Characteristics and Clinical Outcomes in Patients With Cirrhosis due to MASLD in Sweden

Liver International, Volume 46, Issue 2, February 2026.
ABSTRACT Background and Aims There is limited real‐world data on the prognosis of patients with cirrhosis due to metabolic dysfunction‐associated steatotic liver disease (MASLD). We sought to describe the characteristics and assess the clinical course of MASLD‐cirrhosis.
Ying Shang, Linnea Widman, Xiao Zhang, Gail Fernandes, Matthew G. Melaragno, Samuel S. Engel, Johan Vessby, Mattias Ekstedt, Hannes Hagström   +8 more
wiley   +1 more source

Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study

Liver International, Volume 46, Issue 2, February 2026.
ABSTRACT Background/Aims Immune checkpoint inhibitors (ICIs) have transformed advanced HCC treatment. The benefit of sequential immunotherapy after prior ICI failure remains unclear. Given the expanded use of atezolizumab plus bevacizumab (Ate/Bev) over the past 5 years, we explored the real‐world outcomes of nivolumab plus ipilimumab (Nivo/Ipi) in ...
Jung Sun Kim, Jeffrey Wong, San‐Chi Chen, David Tai, Hannah Yang, Youngun Kim, Beodeul Kang, Ilhwan Kim, Hyeyeong Kim, Chansik An, Su Jin Jang, Masatoshi Kudo, Ho Yeong Lim, Chan Kim, Thomas Yau, Hong Jae Chon   +15 more
wiley   +1 more source

Portal hypertension contributes to ascites formation via the Piezo1-nuclear factor kappa-B-aquaporin1 pathway in liver cirrhosis. [PDF]

Exp Mol Med
Wei N, Du L, Xiao Z, Zhang L, Zhou Y, Gao H, Liu M, Wang C, Hou X, Li Y, Song Y.   +10 more
europepmc   +1 more source

Partial Splenic Embolization for Portal Hypertension Before Radical Nephrectomy in Renal Cell Carcinoma Patient: A Case Report. [PDF]

IJU Case Rep
Watanabe S, Tamura K, Watanabe K, Matsushita Y, Watanabe H, Motoyama D, Inamoto T.   +6 more
europepmc   +1 more source

Partial splenectomy and pericardial devascularization for symptomatic patients with portal hypertension: a single-center retrospective study. [PDF]

BMC Surg
Zhang Y, Wang S, Yang J, Bu J, Liang F.
europepmc   +1 more source

Gut microbiota analysis in cirrhosis and non-cirrhotic portal hypertension suggests that portal hypertension can be main factor of cirrhosis-specific dysbiosis. [PDF]

Sci Rep
Gulyaeva K, Nadinskaia M, Maslennikov R, Aleshina Y, Goptar I, Lukashev A, Poluektova E, Ivashkin V.   +7 more
europepmc   +1 more source